Modified-Release T-Type Calcium Channel Formulations for Sustained Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for diseases associated with aberrant T-type calcium channel function, such as epilepsy and mood disorders, lack effective modulation and sustained release mechanisms, leading to inadequate therapeutic outcomes.
Innovation Solution
Development of pharmaceutical compositions comprising a compound of formula (I) or its pharmaceutically acceptable salt, combined with modified-release polymers like HPMC, to create oral dosage forms that control the release rate, providing sustained modulation of T-type calcium channels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If immediate-release formulations are used, then rapid onset of action is achieved, but therapeutic duration is insufficient and peak concentration causes side effects
Solution Approach 1:
The patent segments the drug release process into multiple phases using different polymer matrices (hydrophilic HPMC and hydrophobic ethyl cellulose) with distinct release characteristics. The hydrophilic matrix provides initial rapid release for quick onset, while the hydrophobic matrix sustains release over extended periods, thereby resolving the contradiction between rapid onset and prolonged duration.
Solution Approach 2:
The patent changes the release rate parameter by using polymers with different hydrophilic-lipophilic balances and molecular weights. By selecting specific HPMC grades (e.g., K100M, K4M) and ethyl cellulose variants, the formulation achieves variable release rates from the same dosage form, enabling both rapid initial release and sustained later release to address the onset-duration contradiction.
2Reliability
If high dose is administered, then therapeutic efficacy is improved, but peak concentration increases causing adverse effects
Solution Approach 1:
The patent implements periodic action through its two-stage release mechanism: an initial release phase providing rapid therapeutic effect, followed by a sustained release phase maintaining therapeutic levels over time. This periodic release pattern ensures consistent therapeutic efficacy while avoiding sustained peak concentrations that cause side effects.
Solution Approach 2:
The patent achieves continuity of useful action by designing a formulation that maintains therapeutic drug levels continuously over an extended period (24-48 hours). The combined polymer system ensures uninterrupted drug availability at sub-peak concentrations, providing reliable therapeutic efficacy without the harmful peaks associated with bolus dosing.
3Reliability
If multiple dosing is required, then therapeutic coverage is improved, but patient compliance deteriorates
Solution Approach 1:
The patent applies preliminary action by pre-engineering the dosage form with built-in extended-release capabilities during manufacturing. The patient receives a single pre-formulated tablet that automatically provides multi-day therapeutic coverage without requiring the patient to perform complex dosing schedules or monitor drug levels, thereby maintaining reliable therapeutic coverage while dramatically improving compliance.
4Ease of manufacture
If conventional formulations are used, then manufacturing simplicity is maintained, but release rate control is insufficient
Solution Approach 1:
The patent uses composite materials by combining HPMC and ethyl cellulose in a single tablet matrix. This composite approach enables sophisticated release rate control (biphasic release pattern) while maintaining relatively simple manufacturing processes. The polymers are mixed in predetermined ratios and compressed into tablets using conventional equipment, achieving precise release profiles without complex manufacturing steps.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions effectively reduce seizure frequency and severity in epilepsy, tremor, and improve mood disorders by sustained drug release, enhancing therapeutic efficacy and reducing peak concentration and time to maximum concentration.
Implementation Method 1
an excipient that functions to modify the release rate of the compound of formula (I) or a pharmaceutically acceptable salt thereof
Implementation Method 2
a modified-release polymer (e.g., a controlled-release polymer, hydrophilic matrix polymers, e.g., an HPMC polymer, hydrophobic matrix polymers (e.g., ethyl cellulose, ethocel), or polyacrylate polymers (e.g., Eudragit RL100, Eudragit RS100))
Data Source
AI summary
Described herein, in part, are dosage forms and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a T-type calcium channel, such as epilepsy and epilepsy syndromes (e.g., absence seizures, juvenile myoclonic epilepsy, or a genetic epilepsy), tremor (e.g., essential tremor), and psychiatric disorder (e.g., mood disorders (e.g., major depressive disorder)). The present invention further comprises methods for modulating the function of a T-type calcium channel.